Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | CCNK | O75909 | 1/20 | 0.32 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7614047 | 1.00 | NTRK1 (0.41) | NTRK1FLT3RAF1CCNA2CDK2 | |
| SCHEMBL7606157 | 0.85 | JAK3 (0.41) | NTRK1FLT3CDK2JAK3MAP3K11 | |
| SCHEMBL7606158 | 0.85 | JAK3 (0.41) | NTRK1FLT3CDK2JAK3MAP3K11 | |
| SCHEMBL7605175 | 0.83 | MAPT (0.44) | NTRK1FLT3RAF1CCNKCDK12 | |
| SCHEMBL7605173 | 0.83 | MAPT (0.44) | NTRK1FLT3RAF1CCNKCDK12 | |
| SCHEMBL7607108 | 0.82 | ALDH1A1 (0.38) | — | |
| SCHEMBL7607104 | 0.82 | ALDH1A1 (0.38) | — | |
| SCHEMBL7613336 | 0.82 | MAP3K11 (0.36) | CCNA2CDK2JAK3MAP3K11 | |
| SCHEMBL7613343 | 0.82 | MAP3K11 (0.36) | CCNA2CDK2JAK3MAP3K11 | |
| SCHEMBL7614310 | 0.82 | JAK3 (0.35) | FLT3CCNKCDK12JAK3MAP3K11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | GLENNON KIMBERLEY CAROLINE (US) | 2002-07-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | PRKDC, PRKX, BMX | NTRK1 1095/4885FLT3 198/4885RAF1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.